Qube Research & Technologies (QRT)’s Generate Biomedicines GENB Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$628K	Buy	+50,221	New	+$613K	﹤0.01%	2662

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Qube Research & Technologies (QRT)'s GENB Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Generate Biomedicines (GENB) in Q1 2026: 50,221 shares worth $628K. The stake represents ﹤0.01% of the portfolio and ranks #2662 among its holdings.

57 funds tracked by Wall St. Rank hold GENB as of Q1 2026.

Qube Research & Technologies (QRT) held 50,221 shares of Generate Biomedicines worth $628K as of Q1 2026.
Generate Biomedicines was a new Qube Research & Technologies (QRT) position in Q1 2026.
Generate Biomedicines made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2662 holding.
57 funds tracked by Wall St. Rank held Generate Biomedicines as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.